Abstract

Iris melanoma is a rare form of uveal melanoma with potential metastic spread. Treatment options include surgical resection, enucleation or irradiation. We analysed visual outcome, complication appearance and management in eight patients with iris melanoma following robotic-assisted CyberKnife treatment. Consecutive patients from the Department of Ophthalmology at University of Munich were included in the study if they had an iris melanoma that was treated with CyberKnife and had a minimum follow-up of 12 months. We evaluated tumor thickness, largest diameter, visual acuity and complications. 8 patients were included in this report. The median age was 74 years (range: 53–86 years). The median follow-up was 23 months (range 12–48 months). Tumor thickness decreased from 2.1 to 1.4 mm on average. Four out of eight patients showed stable or increased visual acuity compared to visual acuity at first visit. We did not find a correlation of applied radiation volume or radiation dose on visual outcome. Radiation keratopathy was the most common complication in five patients. No recurrences were noted. Robotic-assisted radiosurgery following CyberKnife is a promising non-invasive, single session treatment option for iris melanoma with comparable results regarding recurrence rate or complications to brachytherapy and proton beam therapy. All included patients showed good visual outcome.

Highlights

  • Iris melanoma is a rare form of uveal melanoma with potential metastic spread

  • The aforementioned patient who was resected as the primary mode of treatment had an iris melanoma confirmed by histopathology of the removed specimen

  • We report on 8 patients that have been treated with robotic assisted CyberKnife (Accuray, Inc.) radiosurgery due to an iris melanoma

Read more

Summary

Introduction

Iris melanoma is a rare form of uveal melanoma with potential metastic spread. Treatment options include surgical resection, enucleation or irradiation. Robotic-assisted radiosurgery following CyberKnife is a promising non-invasive, single session treatment option for iris melanoma with comparable results regarding recurrence rate or complications to brachytherapy and proton beam therapy. The presence of an iris nevus is quite common, representing 25% of all iris lesions in children and 47% of all iris lesions in middle-aged and senior ­adults[3] It is a risk factor for the later development of an iris melanoma. Several studies found predictive clinical factors for growth of iris nevus into melanoma These clinical features include hyphema, 4:00 to 9:00 clock hour tumor location, patient age under 40 years, ectropium uveae, the presence of a feeder vessel, nodule formation and diffuse m­ alignancy[6,7]. Tumor related death occurs in approximately 5–10% of patients, and increases with tumor thickness of more than 4 ­mm[9]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call